Table of Contents Author Guidelines Submit a Manuscript
Journal of Toxicology
Volume 2014 (2014), Article ID 839597, 5 pages
http://dx.doi.org/10.1155/2014/839597
Research Article

Resveratrol Sensitizes Selectively Thyroid Cancer Cell to 131-Iodine Toxicity

Department of Radiopharmacy, Faculty of Pharmacy, Pharmaceutical Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran

Received 2 July 2014; Revised 25 August 2014; Accepted 25 August 2014; Published 3 September 2014

Academic Editor: Brad Upham

Copyright © 2014 Seyed Jalal Hosseinimehr and Seyed Amir Hossein Hosseini. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. J. Robbins and M. J. Schlumberger, “The evolving role of 131I for the treatment of differentiated thyroid carcinoma,” Journal of Nuclear Medicine, vol. 46, supplement 1, pp. 28S–37S, 2005. View at Google Scholar · View at Scopus
  2. S. J. Hosseinimehr, “Flavonoids and genomic instability induced by ionizing radiation,” Drug Discovery Today, vol. 15, no. 21-22, pp. 907–918, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. Z. Noaparast and S. J. Hosseinimehr, “Radioprotective agents for the prevention of side effects induced by radioiodine-131 therapy,” Future Oncology, vol. 9, no. 8, pp. 1145–1159, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. J. B. Little, “Radiation carcinogenesis,” Carcinogenesis, vol. 21, no. 3, pp. 397–404, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. S. J. Hosseinimehr, “Potential utility of radioprotective agents in the practice of nuclear medicine,” Cancer Biotherapy and Radiopharmaceuticals, vol. 24, no. 6, pp. 723–731, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. K. H. Bohuslavizki, W. Brenner, S. Lassmann et al., “Quantitative salivary gland scintigraphy—a recommended examination prior to and after radioiodine therapy,” NuklearMedizin, vol. 36, no. 3, pp. 103–109, 1997. View at Google Scholar · View at Scopus
  7. S. M. Chow, “Side effects of high-dose radioactive iodine for ablation or treatment of differentiated thyroid carcinoma,” Journal of the Hong Kong College of Radiologists, vol. 8, no. 3, pp. 127–135, 2005. View at Google Scholar · View at Scopus
  8. D. van Nostrand, J. Neutze, and F. Atkins, “Side effects of “rational dose” iodine-131 therapy for metastatic well-differentiated thyroid carcinoma,” Journal of Nuclear Medicine, vol. 27, no. 10, pp. 1519–1527, 1986. View at Google Scholar · View at Scopus
  9. A. M. Samuel, T. P. Unnikrishnan, N. S. Baghel, and B. Rajashekharrao, “Effect of radioiodine therapy on pulmonary alveolar-capillary membrane integrity,” Journal of Nuclear Medicine, vol. 36, no. 5, pp. 783–787, 1995. View at Google Scholar · View at Scopus
  10. M. A. Walter, C. P. Turtschi, C. Schindler, P. Minnig, J. Müller-Brand, and B. Müller, “The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study,” Journal of Nuclear Medicine, vol. 48, no. 10, pp. 1620–1625, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Nakada, T. Ishibashi, T. Takei et al., “Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?” Journal of Nuclear Medicine, vol. 46, no. 2, pp. 261–266, 2005. View at Google Scholar · View at Scopus
  12. M. Ballardin, F. Gemignani, L. Bodei et al., “Formation of micronuclei and of clastogenic factor(s) in patients receiving therapeutic doses of iodine-131,” Mutation Research, vol. 514, no. 1-2, pp. 77–85, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Gutiérrez, E. Carbonell, P. Galofré, A. Creus, and R. Marcos, “Cytogenetic damage after 131-iodine treatment for hyperthyroidism and thyroid cancer: a study using the micronucleus test,” European Journal of Nuclear Medicine, vol. 26, no. 12, pp. 1589–1596, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Watanabe, H. Kanegane, S. Kinuya et al., “The radiotoxicity of 131I therapy of thyroid cancer: assessment by micronucleus assay of B lymphocytes,” Journal of Nuclear Medicine, vol. 45, no. 4, pp. 608–611, 2004. View at Google Scholar · View at Scopus
  15. A. Csiszar, “Anti-inflammatory effects of resveratrol: Possible role in prevention of age-related cardiovascular disease,” Annals of the New York Academy of Sciences, vol. 1215, no. 1, pp. 117–122, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Szekeres, P. Saiko, M. Fritzer-Szekeres, B. Djavan, and W. Jäger, “Chemopreventive effects of resveratrol and resveratrol derivatives,” Annals of the New York Academy of Sciences, vol. 1215, no. 1, pp. 89–95, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. A. F. Fernández and M. F. Fraga, “The effects of the dietary polyphenol resveratrol on human healthy aging and lifespan,” Epigenetics, vol. 6, no. 7, pp. 870–874, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. H.-L. Zhu, “Resveratrol and its analogues: promising antitumor agents,” Anti-Cancer Agents in Medicinal Chemistry, vol. 11, no. 5, pp. 479–490, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. S. H. Kim, J. H. Park, Y. J. Kim, and K. H. Park, “The neuroprotective effect of resveratrol on retinal ganglion cells after optic nerve transection,” Molecular Vision, vol. 19, pp. 1667–1676, 2013. View at Google Scholar · View at Scopus
  20. X.-P. Shi, S. Miao, Y. Wu et al., “Resveratrol sensitizes tamoxifen in antiestrogen-resistant breast cancer cells with epithelial-mesenchymal transition features,” International Journal of Molecular Sciences, vol. 14, no. 8, pp. 15655–15668, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Hedayati, N. Shafaghati, and S. J. Hosseinimehr, “Resveratrol mitigates genotoxicity induced by iodine-131 in primary human lymphocytes,” Radiation and Environmental Biophysics, vol. 52, no. 2, pp. 287–291, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Sebastià, A. Montoro, A. Montoro et al., “Assessment in vitro of radioprotective efficacy of curcumin and resveratrol,” Radiation Measurements, vol. 46, no. 9, pp. 962–966, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Chen, X. Jiang, Y. Hu, and Z. Zhang, “The protective role of resveratrol in the sodium arsenite -induced oxidative damage via modulation of intracellular GSH homeostasis,” Biological Trace Element Research, vol. 155, no. 1, pp. 119–131, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Ö. Kavas, P. A. Ayral, and A. H. Elhan, “The effects of resveratrol on oxidant/antioxidant systems and their cofactors in rats,” Advances in Clinical and Experimental Medicine, vol. 22, no. 2, pp. 151–155, 2013. View at Google Scholar · View at Scopus
  25. M. Singh, K. Bhui, R. Singh, and Y. Shukla, “Tea polyphenols enhance cisplatin chemosensitivity in cervical cancer cells via induction of apoptosis,” Life Sciences, vol. 93, no. 1, pp. 7–16, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. S. A. Ashrafi, S. J. Hosseinimehr, K. Varmira, and S. M. Abedi, “Radioimmunotherapy with 131I-bevacizumab as a specific molecule for cells with overexpression of the vascular endothelial growth factor,” Cancer Biotherapy and Radiopharmaceuticals, vol. 27, no. 7, pp. 420–425, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Shi, S. Yang, S. Troup et al., “Resveratrol induces apoptosis in breast cancer cells by E2F1-mediated up-regulation of ASPP1,” Oncology Reports, vol. 25, no. 6, pp. 1713–1719, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Shih, F. B. Davis, H.-Y. Lin, and P. J. Davis, “Resveratrol induces apoptosis in thyroid cancer cell lines via a MAPK- and p53-dependent mechanism,” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 3, pp. 1223–1232, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. X. Zhu, Q. Liu, M. Wang et al., “Activation of Sirt1 by resveratrol inhibits TNF-α induced inflammation in fibroblasts,” PloS ONE, vol. 6, no. 11, Article ID e27081, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. B. Liu, Z. Zhou, W. Zhou et al., “Resveratrol inhibits proliferation in human colorectal carcinoma cells by inducing G1/Sphase cell cycle arrest and apoptosis through caspase/cyclinCDK pathways,” Molecular Medicine Reports, vol. 10, no. 4, pp. 1697–1702, 2014. View at Publisher · View at Google Scholar
  31. C. Zhou, J. Ding, and Y. Wu, “Resveratrol induces apoptosis of bladder cancer cells via miR21 regulation of the Akt/Bcl2 signaling pathway,” Molecular Medicine Reports, vol. 9, no. 4, pp. 1467–1473, 2014. View at Google Scholar
  32. D. Hotnog, M. Mihaila, I. V. Lancu et al., “Resveratrol modulates apoptosis in 5-fluorouracyl treated colon cancer cell lines,” Roumanian Archives of Microbiology and Immunology, vol. 72, no. 4, pp. 255–264, 2013. View at Google Scholar
  33. L. H. Duntas, “Resveratrol and its impact on aging and thyroid function,” Journal of Endocrinological Investigation, vol. 34, no. 10, pp. 788–792, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. H. J. Kang, Y.-K. Youn, M.-K. Hong, and L. S. Kim, “Antiproliferation and redifferentiation in thyroid cancer cell lines by polyphenol phytochemicals,” Journal of Korean Medical Science, vol. 26, no. 7, pp. 893–899, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. H.-Y. Lin, H.-Y. Tang, A. Shih et al., “Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic,” Steroids, vol. 72, no. 2, pp. 180–187, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. X. M. Yu, R. Jaskula-Sztul, K. Ahmed, A. D. Harrison, M. Kunnimalaiyaan, and H. Chen, “Resveratrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch1 signaling and suppresses cell growth,” Molecular Cancer Therapeutics, vol. 12, no. 7, pp. 1276–1287, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Sebai, S. Hovsépian, E. Ristorcelli, E. Aouani, D. Lombardo, and G. Fayet, “Resveratrol increases iodide trapping in the rat thyroid cell line FRTL-5,” Thyroid, vol. 20, no. 2, pp. 195–203, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Frombaum, S. le Clanche, D. Bonnefont-Rousselot, and D. Borderie, “Antioxidant effects of resveratrol and other stilbene derivatives on oxidative stress and NO bioavailability: potential benefits to cardiovascular diseases,” Biochimie, vol. 94, no. 2, pp. 269–276, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Iuga, J. R. Alvarez-Idaboy, and N. Russo, “Antioxidant activity of trans-resveratrol toward hydroxyl and hydroperoxyl radicals: a quantum chemical and computational kinetics study,” Journal of Organic Chemistry, vol. 77, no. 8, pp. 3868–3877, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Quincozes-Santos, L. D. Bobermin, A. Latini et al., “Resveratrol protects C6 astrocyte cell line against hydrogen peroxide-induced oxidative stress through heme oxygenase 1,” PLoS ONE, vol. 8, no. 5, Article ID e64372, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. N. Sebastià, M. Almonacid, J. I. Villaescusa et al., “Radioprotective activity and cytogenetic effect of resveratrol in human lymphocytes: an in vitro evaluation,” Food and Chemical Toxicology, vol. 51, no. 1, pp. 391–395, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Fu, Y. Wang, L. Du et al., “Resveratrol inhibits ionising irradiation-induced inflammation in MSCs by activating Sirt1 and limiting NLRP-3 inflammasome activation,” International Journal of Molecular Sciences, vol. 14, no. 7, pp. 14105–14118, 2013. View at Publisher · View at Google Scholar · View at Scopus